SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGPBiotechnology
+$0.45 today
- Market cap
- $993.14M
- Beta
- -0.34
- P/E (TTM)
- -14.1
- EPS (TTM)
- -$1.32
Volume 0.10M
Average 0.09M
SGP Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
SpyGlass Pharma, Inc. Common StockNASDAQ: SGP
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets of $258.39M in Q1 FY2026
Q1 FY2026 total assets was $258.39M.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 115.87M USD
- Year-over-year change
- —
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 115.87M | — |
Total Assets vs competitors
How SGP compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Sep 2026 | $31.37B USD | -0.4% | +2.6% | |
| Jun 2026 | $13.86B USD | +0.2% | +8.0% | |
| Jun 2026 | $920.52M USD | -6.7% | -6.0% | |
| Mar 2026 | $732.53M USD | +80.5% | +75.6% | |
| Apr 2026 | $451.12M USD | -1.4% | +3.3% | |
| Mar 2026 | $303.99M USD | -2.9% | +27.6% | |
| Mar 2026 | $288.22M USD | -20.5% | +26.4% | |
SGPSpyGlass Pharma, Inc. Common Stock | Mar 2026 | $258.39M USD | — | — |
| Mar 2026 | CHF 243.26M CHF | +19.1% | +85.4% | |
| Mar 2026 | $109.7M USD | -15.4% | -18.5% | |
| Peer median (excluding SGP) | — | -1.4% | +8.0% | |
Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
SpyGlass Pharma, Inc. Common Stock
NASDAQ:SGP
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.